Psychological Medicine; Cambridge Vol. 49, Iss. 8, (Jun 2019): 1233-1236. DOI:10.1017/S0033291718004166. In the wake of a ‘viewpoint’ article examining whether it is right to continue to regard CBT as a gold standard for depression and anxiety (Leichsenring and Steinert, 2017), we consider the current status of this form of therapy in schizophrenia and the related psychotic disorders that are typically included in trials (schizoaffective disorder, delusional disorder, and psychosis not otherwise specified). [...]there was no evidence of effectiveness against relapse, when compared with either standard care [relative risk (RR) 0.85 (95% CI 0.50–1.41), three trials] or with other active treatments [RR 1.05 (CI 0.85–1.30), four trials]. [...]a view finds echoes in UK clinical guidelines: NICE (2009) emphasized not only effects on psychotic symptoms but also reduction of distress associated with symptoms, promotion of social and educational recovery, and reduction of depression and social anxiety. A preliminary report of this study (Bechdolf et al., 2017) found a smaller number of transitions in the CBT group compared with clinical management (19.2% v. 30.0%), but the difference did not reach statistical significance.. To read the full article, log in using your NHS OpenAthens details.